shenglin ge Ge

Prof. shenglin ge Ge


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
CACheng An
Cheng An
FSFei Sun
Fei Sun
CLCan Liu
Can Liu
SHShaojun Huang
Shaojun Huang
TXTao Xu
Tao Xu
SGshenglin ge Ge
shenglin ge Ge

8 May 2024 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
CACheng An
Cheng An
ZLZhen Li
Zhen Li
YCYao Chen
Yao Chen
SHShaojun Huang
Shaojun Huang
FYFan Yang
Fan Yang
SGshenglin ge Ge
shenglin ge Ge
The cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase-stimulator of interferon genes (cGAS-STING) signaling pathway, an important component of the innate immune system, is involved in the development of several diseases. Ectopic DNA-induced inflammatory responses are involved in several pathological processes. Repeated damage to tissues and metabolic organelles releases a large number of damage-associated molecular patterns (mitochondrial DNA, nuclear DNA, and exogenous DNA). The DNA fragments released into the cytoplasm are sensed by the sensor cGAS to initiate immune responses through the bridging protein STING. Many recent studies have revealed a regulatory role of the cGAS-STING signaling pathway in cardiovascular diseases (CVDs) such as myocardial infarction, heart failure, atherosclerosis, and aortic dissection/aneurysm. Furthermore, increasing evidence suggests that inhibiting the cGAS-STING signaling pathway can significantly inhibit myocardial hypertrophy and inflammatory cell infiltration. Therefore, this review is intended to identify risk factors for activating the cGAS-STING pathway to reduce risks and to simultaneously further elucidate the biological function of this pathway in the cardiovascular field, as well as its potential as a therapeutic target.

18 May 2023 in The FASEB Journal
Verified
Journal Article
Closed access
FSFei Sun
Fei Sun
CACheng An
Cheng An
CLCan Liu
Can Liu
YHYing Hu
Ying Hu
YSYue Su
Yue Su
SGshenglin ge Ge
shenglin ge Ge

1 June 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
JYJunfa Yang
Junfa Yang
CXChangqing Xu
Changqing Xu
MWMaomao Wu
Maomao Wu
YWYing Wu
Ying Wu
XJXiaodi Jia
Xiaodi Jia
LZLingling Zhang
Lingling Zhang

1 April 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
CLCan Liu
Can Liu
ZGZhongxuan Gui
Zhongxuan Gui
CACheng An
Cheng An
FSFei Sun
Fei Sun
XGXiaotian Gao
Xiaotian Gao
SGshenglin ge Ge
shenglin ge Ge
Myocardial ischemia-reperfusion injury (MIRI) is involved in the pathogenesis of multiple cardiovascular diseases. This study elucidated the biological function of lysine acetyltransferase 5 (KAT5) in cardiomyocyte pyroptosis during MIRI. Oxygen-glucose deprivation/reoxygenation and left anterior descending coronary artery ligation were used to establish MIRI models. Here we show, KAT5 and STIP1 homology and U-box-containing protein 1 (STUB1) were downregulated, while large tumor suppressor kinase 2 (LATS2) was upregulated in MIRI models. KAT5/STUB1 overexpression or LATS2 silencing repressed cardiomyocyte pyroptosis. Mechanistically, KAT5 promoted STUB1 transcription via acetylation modulation, and subsequently caused ubiquitination and degradation of LATS2, which activated YAP/β-catenin pathway. Notably, the inhibitory effect of STUB1 overexpression on cardiomyocyte pyroptosis was abolished by LATS2 overexpression or KAT5 depletion. Our findings suggest that KAT5 overexpression inhibits NLRP3-mediated cardiomyocyte pyroptosis to relieve MIRI through modulation of STUB1/LATS2/YAP/β-catenin axis, providing a potential therapeutic target for MIRI.

29 March 2021 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
TSTao Sun
Tao Sun
QGQian Gong
Qian Gong
YWYing Wu
Ying Wu
ZSZhiming Shen
Zhiming Shen
YZYan Zhang
Yan Zhang
JDJing-Si Duan
Jing-Si Duan